Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05600036 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
A Phase 2 study, sponsored by Alumis.
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT05600036 is a Phase 2 study that has completed, run by Alumis. The registered enrollment target is 228 participants.
The verdict
NCT05600036, a Phase 2 study, has completed, sponsored by Alumis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG ESK-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05600036
The ClinicalTrials.gov registry entry for NCT05600036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05600036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05600036 about?
NCT05600036 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis". This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
What is the current status of trial NCT05600036?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2022-09-27. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT05600036?
The interventions under investigation include: Placebo (DRUG), ESK-001 (DRUG).
Who is sponsoring clinical trial NCT05600036?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.